Trial Profile
Neo-Adjuvant Treatment With the CDK4,6 Inhibitor Palbociclib in HER2-positive and ER-positive Breast Cancer: Effect on Ki67 and Apoptosis Before, During and After Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Palbociclib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Early breast cancer
- Focus Therapeutic Use
- Acronyms NA-PHER2
- 07 Mar 2022 Results published in the Clinical Cancer Research
- 08 Jun 2021 Results assessing RNA-sequence on core-biopsies obtained pre-treatment at day 14 and on residual disease at surgery presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 14 Jul 2020 Status changed from active, no longer recruiting to completed.